Skip to content
Back to news
IndustryNovember 20, 2026

AstraZeneca Reportedly Cuts 600 US Sales Roles in $1.5B Savings Drive

AstraZeneca Reportedly Cuts 600 US Sales Roles in $1.5B Savings Drive: PharmoniQ news card

AstraZeneca has cut about 600 jobs on its US respiratory and immunology commercial teams, Bloomberg News reported, citing people familiar with the matter. The cuts are part of a cost-savings program the company announced in late October. AstraZeneca declined to comment on the report, according to Reuters.

What happened

According to the Bloomberg report, as carried by Reuters, the roles sit in the sales and marketing teams that support the company's lung and immune disease medicines in the United States. Some of the affected employees are expected to be moved into other roles inside the company.

Fierce Pharma, also citing Bloomberg, said at least some of the affected staff had been promoting the asthma inhalers Breztri and Airsupra. It added that AstraZeneca has also scaled back its US work with Syneos Health, a contract sales organization.

  • Jobs: about 600, in US respiratory and immunology commercial teams.
  • Program: about $1.5 billion in yearly savings over three years, to be put back into the drug pipeline.
  • Company response: AstraZeneca declined to comment on the report.

Why it matters

Respiratory and immunology is a large business for AstraZeneca. Reuters reported it brought in $2.5 billion in the third quarter, or 16% of total revenue. The company is still aiming for $80 billion in yearly revenue by 2030.

Recent sales of the two inhalers named in the report have been mixed. Fierce Pharma said US sales of Breztri rose 2% to $170 million in the third quarter. US sales of Airsupra fell 3% to $43 million.

The cuts come weeks after leaders said the savings plan would not shrink the company overall. Fierce Pharma reported that chief financial officer Aradhana Sarin said the restructuring would not lead to a net cut in staff. Chief executive Pascal Soriot argued that a $1.5 billion investment would create jobs. Fierce also counts AstraZeneca among three large drugmakers that have kept adding staff since 2021.

What it means for people in the industry

For sales staff, the report shows that a company can cut field roles in one area while it says it is investing overall. The reported cuts land on US respiratory and immunology teams, not on the whole company.

The sources do not say which states or offices are affected, or how many of the 600 people will be moved into other roles. The reported pullback from Syneos Health may also matter for contract sales staff. More detail could come in state layoff notices or at AstraZeneca's next results.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.